Utilizing the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated with Adjuvant Radiotherapy.
Variability exists in the adjuvant treatment for endometrial cancer (EC) based on surgical pathology and institutional preference. The radiosensitivity index (RSI) is a previously validated multi-gene expression index that estimates tumor radiosensitivity. We evaluate RSI as a genomic predictor for pelvic failure (PF) in EC patients treated with adjuvant radiotherapy. Using our institutional XXX, we identified EC patients treated between January 1999 and April 2011 of primarily endometrioid histology (n=176; 86%) with receipt of various adjuvant therapies. The RSI 10-gene signature was calculated for each sample using the previously published algorithm. Radiophenotype was determined using the previously identified cutpoint where RSI ≥0.375 denotes radioresistance (RR) and RSI <0.375 describes radiosensitivity (RS). A total of 204 patients were identified of which 83 (41%) were treated with adjuvant radiotherapy. Median follow-up was 38.5 months. All patients underwent hysterectomy with bilateral salpingo-oophorectomy with the majority undergoing lymph node dissection (n=181; 88%). In patients treated with radiation, RR tumors were more likely to experience PF (3-year pelvic control 84% vs 100%; P=0.02) with worse PF-free survival (PFFS) (3-year PFFS 65% vs. 89%; P=0.04). Furthermore, in the patients who did not receive RT, there was no difference in PF (P=0.87) or PFFS (P=0.57) between the RR/RS tumors. On multivariable analysis (MVA), factors that continued to predict for PF included the RR phenotype (HR=12.2, P=0.003), lymph node involvement (HR=4.4, P=0.02), and serosal and/or adnexal involvement (HR=5.3, P=0.01). On MVA, RSI was found to be a significant predictor of PF in patients treated with adjuvant radiotherapy. We propose utilizing RSI to predict which patients are at higher risk for failing in the pelvis and may be candidates for treatment escalation in the adjuvant setting.